EICHOR
● Active Not Recruiting
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
Condition: Arthritis, Psoriatic · Sponsor: Janssen Pharmaceutica N.V., Belgium
About this study
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (155)
| OMI | Buenos Aires, Argentina | — |
| Hospital Italiano de Buenos Aires | Buenos Aires, Argentina | — |
| Hospital J. M. Ramos Mejía | Buenos Aires, Argentina | — |
| Hospital Cordoba | Córdoba, Argentina | — |
| MR Medicina Reumatologica | San Fernando, Argentina | — |
| The Queen Elizabeth Hospital | Adelaide, Australia | — |
| Footscray Hospital, Western Health | Footscray, Australia | — |
| Royal North Shore Hospital | St Leonards, Australia | — |
| LKH-Univ. Klinikum Graz | Graz, Austria | — |
| Kepler Universitatsklinikum GmbH | Linz, Austria | — |
| Medizinische Universitaet Wien | Vienna, Austria | — |
| Evang. Krankenhaus Gemein. Betriebgesm. Mbh | Vienna, Austria | — |
+ 143 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.